Americans will eat about 2bn chicken nuggets this year, give or take a few hundred million. This deep-fried staple is a way of profiting off the bits that are left after the breast, legs and wings are lopped off the 9 billion or so factory-farmed chickens slaughtered in the US every year. Like much else that is ubiquitous in contemporary life, the production of nuggets is controlled by a small group of massive companies that are responsible for a litany of social and ecological harms. And, like many of the commodities produced by this system, they are of dubious quality, cheap, appealing and easy to consume. Nuggets are not even primarily meat, but mostly fat and assorted viscera including epithelium, bone, nerve and connective tissue made palatable through ultra-processing. As the political economists Raj Patel and Jason Moore have argued, they are a homogenised, bite-size avatar of how capitalism extracts as much value as possible from human and nonhuman life and labour.
But if chicken nuggets are emblematic of modern capitalism, then they are ripe for disruption. Perhaps their most promising challenger is a radically different sort of meat: edible tissue grown in vitro from animal stem cells, a process called cellular agriculture. The sales pitch for the technology is classic Silicon Valley: unseat an obsolete technology in this case, animals and do well by doing good.
Intensive animal agriculture, which produces nuggets and most of the other meat that Americans consume, keeps the price of meat artificially low by operating at huge economies of scale, and shifting the costs of this production on to people, animals and the planet. The industry deforests the land, releases hundreds of millions of tonnes of greenhouse gases every year, creates terrible working conditions at abattoirs, and necessitates abhorrent animal treatment on farms, all while engaging in price fixing, lobbying for environmental and labour deregulation, and pushing for unconstitutional anti-whistleblower laws.
The problem is that people love eating meat, with global production and consumption growing steadily, and little sign of a collective vegan epiphany on the horizon. This makes intensive animal agriculture a wicked problem: something so obviously detrimental, and yet so politically and socially entrenched, that it is unclear where reformers should even start. Cellular agriculture, however, seems to offer a potential socio-technological hack: it could eliminate much of the damage that system causes, without requiring consumers to give up meat.
Get the Guardian's award-winning long reads sent direct to you every Saturday morning
Long the stuff of science fiction and philosophical musing, cellular agriculture is fast becoming a reality. In December 2020, the San Francisco-based food company Eat Just launched the worlds first commercially available cell-based meat at the private 1880 club in Singapore. Its form a chicken nugget was partly symbolic, partly necessary: the technology isnt advanced enough yet to replicate a chickens breast, wings or legs. But the entire animal kingdom is ripe for replication. The first cellular agriculture prototype presented to the public was a burger patty created by a research team at Maastricht University in 2013. The company that grew out of that project, Mosa Meat, is now speeding toward market release of cell-based beef. Aleph Farms, an Israeli startup, has 3D printed a cellular ribeye steak. Shiok Meats of Singapore is cultivating shrimp without the shrimp. Berkeleys Finless Foods is tackling the endangered bluefin tuna. And Australia-based Vow wants to diversify beyond the most commonly eaten species to zebra, yak and kangaroo.
Most of this development is being carried out by a fast-multiplying number of startups clustered in the worlds tech hubs. They are supported by a global network of ultrawealthy investors and venture capitalists who have ploughed more than $7bn into alternative proteins over the past decade, including about $900m into cultured meat. Richard Branson, Bill Gates and a slew of other billionaires are investors and hype men for the technology; the Maastricht burger was funded in part by Google co-founder Sergey Brin. But major corporations are getting in on the ground floor, with the pharmaceutical behemoth Merck investing in Mosa Meats and the meat giant Tyson Foods buying a stake in Silicon Valleys Upside Foods.
That private capital is working overtime to disrupt farming with synthetic biology is likely all that boosters and critics alike need to know about the technology. Techno-optimists see a future of widely available clean meat, as ecologically and ethically superior to the original as solar power is to coal. Opponents see corporate-controlled lab meat that slots all too comfortably into a broken capitalist food system.
Both sides have some truth to them, but they wrongly assume that the outcomes have been determined in advance. There was nothing predestined about the forces that drove the food system to ever-intensifying mechanisation, labour exploitation and environmental ruin in the past century; it happened because of political choices, collective and individual. Similarly, we need not be prisoners of tech monopolists slapping grey vat meat on our plates. What we need is an analysis of the possibilities of cellular agriculture what this novel food technology, with the right policies and investments, could make possible for consumers, workers, animals and the environment.
To grasp the promise and perils of cellular agriculture, we need to understand the system it might change. Our current animal agriculture policies and practices do immense damage, and uprooting them will require enormous collective effort, but history shows that the system can change radically, even in the course of a generation.
For consumers, the current food system is defined by abundance and low prices. Americans spend just under 10% of their disposable income on food, among the lowest rates in the world, and eat a whopping 122kg of meat each a year, including 55kg of chicken. (For comparison, in the UK the numbers are lower but still unsustainable, at about 80kg of meat per person, including 32kg of chicken.) But theres a high price to pay for low costs. Today, billions of genetically indistinguishable chickens live and die in squalid misery in supersized facilities designed around high efficiency and low margins. Three major processing companies Tyson, Perdue and Koch control the majority of the US market for chicken meat. The industry either functions as a quasi-monopsony, with a small number of buyers imposing prices and conditions on producers, or in some cases is vertically integrated so that Big Chicken directly controls most of the value chain.
This gives the industry tremendous economic power over farmers, workers and consumers. Farm owners on contract with major processors are forced to compete so hard against one another that many are lucky if they barely break even. Chicken processing is gruelling, low-paid, dangerous work on high-speed slaughter lines that kill 140 birds a minute. A 2015 Oxfam report on the industry told stories of workers forced to wear nappies on the line because they were denied toilet breaks, and of others crippled by repetitive motion injuries. Meanwhile, chicken giants including Tyson and Pilgrims Pride recently settled nine-figure lawsuits for price fixing brought by supermarkets, restaurants and individual consumers. The size and wealth of these companies has also given them remarkable political heft. One of the most potent recent examples of this came in April 2020 when, at the industrys urging, then-president Donald Trump invoked the Defense Production Act to keep abattoirs open, even as thousands of workers fell ill with Covid-19.
Meanwhile, cramming animals into factory farms and clearing land for more feed crops has increased the likelihood of outbreaks of zoonotic diseases such as swine flu, avian influenza or Covid-19. The system disables and kills even more people through non-infectious diseases: in the past 60 years, changes in diet have contributed to extraordinary increases in the number of Americans with obesity, diabetes and heart conditions.
Two things brought us to this grim place. The first is a profit-led drive for ever-increasing efficiency in agriculture, which has been in train for at least two centuries. The second is the proliferation of agricultural policies that, in the US in particular, have created an endless trough of subsidies, but barely any labour or environmental regulations. The whole system has been engineered primarily for the benefit of the owners of farmland and huge agribusiness firms, and at the expense of the public.
Nowhere is this more visible than in the case of meat. Animal slaughter was industrialised by the meatpackers of late-19th-century Chicago, where 40,000 mostly low-wage Black and immigrant labourers slaughtered millions of cattle and swine every year on so-called disassembly lines. This high-volume model required standardised inputs grain and the animals that ate it suitable for industrial processing. This was supported by the US government, which early in the 20th century launched research programmes, tax breaks and technology drives designed to facilitate intensive agriculture to turn every farm into a factory, as the historian Deborah Fitzgerald puts it.
All this led to the advent of factory farms after the second world war. Chickens had not previously been a staple of the American diet, but they proved to be particularly well suited to industrialisation because they reproduce quickly and their size and egg-laying capacity are easily modified through breeding. Meat companies set about creating a market for chicken meat through relentless advertising campaigns, and the factory-farming model soon spread to pigs and influenced the development of ever-larger feedlots for cattle. The environmental health scholar Ellen Silbergeld has described this as the chickenisation of agriculture.
There are plenty of smart, progressive critiques of this system, but most of the suggested alternatives involve breaking up the food giants and downsizing or diversifying US farms. But antitrust policy alone wont address the harms done to animals, labour or the environment by modern animal agriculture. Breaking up big operations could simply generate more, if maybe slightly smaller and slower factory farms. As for genuinely small farms engaged in more holistic agriculture, the theory is that they are more environmentally sustainable, protect jobs and keep local stores stocked with juicy heirloom tomatoes and humanely raised beef. But building an agricultural system around small farmers that is economically viable and can benefit most of the population could be a tall order. Many people dont want, cant afford or dont have access to organic, free-range, farm-to-fork meat and produce. What they can get are nuggets. And proponents of going small often struggle to explain how their ideas can be done on a big enough scale and at a low enough price to challenge the status quo, and in a timeframe that responds to our ongoing ecological crisis.
Meanwhile, experts on the environmental impacts of the food system mostly concur that we need to eat much less meat. Some propose vegetarian and vegan diets as solutions. And even meat-inclusive proposals, like the EAT-Lancet commissions model diet, recommend steep reductions, especially in the global north, and suggest a move away from the factory farming model of meat production. However, there are no signs that anything except outright bans on factory-farmed meat can achieve the required cuts and that, for now, is a political non-starter.
This is where cellular agriculture comes in. The thing that could help solve the chickenisation of our food system is not pasture-raised hens, but mass-produced chickenless nuggets.
In 1931, Winston Churchill proclaimed that technology would one day allow humans to escape the absurdity of growing a whole chicken in order to eat the breast or wing by growing these parts separately under a suitable medium. As recently as the late 90s, the remark could be cited as an example of the futility of futurology. But a rapid development of biotechnology and medical science is making cellular agriculture a reality. Stem cells, the basic building blocks of most organisms, were identified in the 60s. Growing in vitro muscle tissue became possible in the 70s, and the first peer-reviewed research on the possibility of in vitro meat production was published in 2005.
For a cutting-edge biotechnology, cellular agriculture is actually a fairly straightforward process. It begins with stem cells, usually harvested from live animals via biopsy. The cells are placed in a bioreactor a temperature- and pressure-controlled aseptic steel vat filled with a nutrient-dense growth medium that is basically a broth of sugars and proteins. Under these conditions, the cells proliferate and differentiate to form tissue. Fresh from the bioreactor, youll have an edible, if not yet appetising substance called wet mass, which must then be processed in various ways to produce nuggets, ground beef and so on. Mimicking more complex cuts of meat a filet mignon, say requires additional techniques, such as growing muscle and fat cells on scaffolds made of a material such as collagen. Its structural engineering, but at a microscopic level.
The potential benefits of this technology are manifold. Most analyses of these processes suggest they would use far less land and water, and have a smaller carbon footprint, than beef and dairy. If powered with clean energy a big but not implausible if they could have less environmental impact than chicken and pork. It would prevent the torture and killing of billions of creatures every year, and also greatly reduce the risk of diseases spreading from animals to humans. Cellular fish could have even greater ecological benefits, through relieving pressure on endangered ecosystems and reducing the extensive pollution caused by the fishing industry.
Rendering abattoirs obsolete would also end their inherently abusive labour practices. The labour required to culture meat is highly technical and involves carefully monitoring, maintaining and adjusting bioreactors without compromising the fragile aseptic environments that cell growth requires. Thats the polar opposite of fast-paced slaughter and dismemberment labour, which results in, on average, two amputations of hands, fingers, feet or limbs a week in the US. Cellular agriculture factories would offer substantially better-paying jobs than abattoirs, and would also be considerably safer and healthier work environments (albeit likely not to the same workforce).
There is a parallel push to develop plant-based animal product alternatives. Given that these kind of foods can be made with existing technology and widely grown plants, and can scale up and reduce costs quickly, they are probably a better bet than cellular agriculture to challenge the conventional animal agriculture industry in the short term. The market for plant-based meat and dairy is forecast to pass $75bn globally in the next five years, and includes faux-chicken nuggets from myriad companies, including Beyond, makers of the eponymous burger. But ultimately the companies behind them are offering artful imitations that they hope consumers will end up choosing instead of meat. Cellular agriculture produces real meat, allowing it to take the $1tn global meat industry head-on. It does all this by taking ethics off the table in the words of the Good Food Institute, an NGO that promotes alternative protein relying on market mechanisms and appealing to consumer choice, and that could improve its chances of disrupting factory farming. Its a moonshot that just might land.
This vision of cellular agriculture seems like just the sort of boosterism that Silicon Valley loves to inspire and exploit. To a growing number of critics, the enterprise smacks of solutionism, the foolhardy belief that technology can sidestep thorny social and political problems. For some scholars of technology, cellular agriculture is yet another exercise in ecomodernist techno-optimism. They argue that it is blind to the fact that actual modernisation has entailed very real, and sometimes violent, effects for people and societies to be modernised, as the Uppsala University geographer Erik Jnsson put it. Many would prefer if everyone simply went vegan or vegetarian.
There are valid concerns that Silicon Valley and food corporations could use technologies such as cellular agriculture to tighten their control over the food supply and greenwash noxious agricultural capitalism. Current meat culturing techniques and stem cell lines are valuable intellectual property, closely guarded by armies of patent lawyers and non-disclosure agreements. Critics worry that this new industry will replicate precisely the opacity and lack of accountability of the one it aims to replace. To them, cellular agriculture embraces the worst parts of the current food regime: mass-produced, nutritionally dubious nuggets sold at homogeneous fast-food joints.
There are three responses to these challenges. The first is that the potential benefits of cellular agriculture outweigh all these costs. If the technology can dramatically diminish the production and consumption of conventional meat, even if it does so using the tools of financialised, neoliberal agri-capitalism, this is still ethically and ecologically preferable to the status quo. Incumbent meat companies such as Tyson and Cargill are not, after all, philanthropic enterprises feeding the world out of the goodness of their hearts, either. Put differently, to suggest that a world of cell meat and one of factory farms are remotely comparable is to lose all sense of perspective on the food system.
The second is that cellular agriculture, at a big enough scale, could help restructure agricultural land use by reducing demand for animal feed, thereby opening up space for more progressive food politics. If a government-financed land bank bought even a small fraction of the 320m hectares currently dedicated to feeding animals in the US, it could resell millions of acres at favourable terms for bold new uses: establishing agro-ecological and regenerative farms that are a foundation for healthier rural communities and landscapes; supporting community and worker-owned farms; providing land to people from communities that have been historically dispossessed and excluded from owning land; returning lands to tribal nations; rewilding and conservation initiatives. Many of these ideas are championed by critics of cultured meat, who often suggest it is incompatible with the holistic, ecological sensibilities of slow, small and local. But all of these ideas become more feasible in a world with commercially viable labriculture.
Finally, theres nothing inherent to cellular agriculture technology that favours venture capital or restrictive intellectual property regimes. Those who want cellular agriculture to live up to its lofty potential shouldnt just be worried about the malignant influence of capital they should be finding practical ways to limit it. Whats needed is the political vision and energy to liberate this technology from the grips of corporate stakeholders, and to use it for the radical project of improving the human and animal condition around the world.
But if cellular agriculture is going to improve on the system it is displacing, then the critics are right: it needs to grow in a way that doesnt externalise the real costs of production on to workers, consumers and the environment. There are serious questions about whether production can scale up safely and affordably, and some cellular agriculture practices need to be cast aside. For instance, many companies current production techniques, including the ones Eat Just used for its Singaporean nuggets, use foetal bovine serum as a cell growth medium, which is harvested from the blood of cow foetuses during slaughter.
But scale may be as much a social and political question as a purely technical one. While some cellular agriculture research is being carried out at public universities with support from NGOs such as GFI and New Harvest, most research and development is being done privately. Substantial capital is needed for research, development and commercialisation. But the fact that the private sector sees potential in a technology that governments have mostly ignored is a political problem. What we need are public institutions that can nurture cellular agriculture and rein it in with public investment, regulation and licensing. It is perfectly plausible that private firms flush with venture capital will find ways to scale and sharply reduce the costs of cultured meat. But they will almost inevitably do so while maximising investor value rather than social welfare.
The challenges to achieving scale and affordability are substantial. An independent analysis for Open Philanthropy estimated that to be commercially viable, cultured wet mass would need to sell at about $25 per kg. Current culturing techniques could put it at about $37 per kg. This creates a paradox. Cultured meat at its current level of development is best suited to replace the most mass-produced, standardised, readily available meat: the chicken nugget. But the Eat Just nuggets were $17 a plate, a price that would flop on the mass market, and may already have been significantly discounted for promotional purposes. Chicken nuggets are far cheaper than $25 per kg, which is closer to what you might pay for free-range beef.
Perhaps the best way to overcome these challenges is to deploy the same strategy that the US government used to industrialise farming a century ago: invest robustly in research and development through public universities, national labs and generous subsidies. Between talk of the Green New Deal and the Biden administrations ambitions for comprehensive climate crisis policy, the window for public investment in environmentally responsible technology is unusually wide. Substantial and continued government investment in cellular agriculture could be a part of whatever legislation emerges. More broadly, governments should learn from economists such as Mariana Mazzucato, who argue that mission-driven public investment in innovation is crucial to serving the public good. We are already seeing some of this sort of proactive investment and regulation in places such as Singapore and Israel.
All this could serve to lower barriers to entry into the industry, and could help with the establishment of regulations, such as a moratorium on foetal bovine serum, and industry-wide safety standards. Regulations and licensing should also require that cultured meat facilities are unionised workplaces, and that, where possible, qualified workers displaced from the conventional meat industry be given preference in hiring. Intellectual property could remain in the public trust.
Most critical visions of cellular agriculture are dystopian: unaccountable corporate giants force-feeding a captive population with fake meat. Ironically, that describes the food system we already have. A world in which the factory-farmed nugget is replaced by the bioreactor-brewed nugget would be a monumental win for animals and the environment. If tied to progressive industrial and agricultural policy, it could also be a win for labour, public investment, land use and champions of sustainable agriculture. No, this would not be a one-shot, magic bullet solution to the many ills of food production; there is no panacea. But its a start. Chicken nuggets might represent everything thats wrong with our current food system, but cellular nuggets might just help build a more sustainable future.
A version of this article first appeared in Logic, a magazine about technology
Follow the Long Read on Twitter at @gdnlongread, listen to our podcasts here and sign up to the long read weekly email here.
See the original post here:
Man v food: is lab-grown meat really going to solve our nasty agriculture problem? - The Guardian
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
Recent Comments